Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 1
2004 6
2005 9
2006 7
2007 7
2008 6
2009 7
2010 3
2011 8
2012 13
2013 18
2014 16
2015 15
2016 19
2017 10
2018 13
2019 17
2020 22
2021 12
2022 14
2023 14
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

228 results

Results by year

Filters applied: . Clear all
Page 1
Identification of ADME genes polymorphic variants linked to trastuzumab-induced cardiotoxicity in breast cancer patients: Case series of mono-institutional experience.
Staropoli N, Scionti F, Farenza V, Falcone F, Luciano F, Renne M, Di Martino MT, Ciliberto D, Tedesco L, Crispino A, Labanca C, Cucè M, Esposito S, Agapito G, Cannataro M, Tassone P, Tagliaferri P, Arbitrio M. Staropoli N, et al. Among authors: tassone p. Biomed Pharmacother. 2024 Mar 27;174:116478. doi: 10.1016/j.biopha.2024.116478. Online ahead of print. Biomed Pharmacother. 2024. PMID: 38547766
Genetic Biomarkers of Sorafenib Response in Patients with Hepatocellular Carcinoma.
Giannitrapani L, Di Gaudio F, Cervello M, Scionti F, Ciliberto D, Staropoli N, Agapito G, Cannataro M, Tassone P, Tagliaferri P, Seidita A, Soresi M, Affronti M, Bertino G, Russello M, Ciriminna R, Lino C, Spinnato F, Verderame F, Augello G, Arbitrio M. Giannitrapani L, et al. Among authors: tassone p. Int J Mol Sci. 2024 Feb 12;25(4):2197. doi: 10.3390/ijms25042197. Int J Mol Sci. 2024. PMID: 38396873 Free PMC article.
Author Correction: The Cyclophilin A-CD147 complex promotes the proliferation and homing of multiple myeloma cells.
Zhu D, Wang Z, Zhao JJ, Calimeri T, Meng J, Hideshima T, Fulciniti M, Kang Y, Ficarro SB, Tai YT, Hunter Z, McMilin D, Tong H, Mitsiades CS, Wu CJ, Treon SP, Dorfman DM, Pinkus G, Munshi NC, Tassone P, Marto JA, Anderson KC, Carrasco RD. Zhu D, et al. Among authors: tassone p. Nat Med. 2024 Apr;30(4):1210. doi: 10.1038/s41591-024-02820-2. Nat Med. 2024. PMID: 38273148 No abstract available.
The impact of PARP inhibitors in the whole scenario of ovarian cancer management: A systematic review and network meta-analysis.
Staropoli N, Ciliberto D, Luciano F, Napoli C, Costa M, Rossini G, Arbitrio M, Labanca C, Riillo C, Del Giudice T, Crispino A, Salvino A, Galvano A, Russo A, Tassone P, Tagliaferri P. Staropoli N, et al. Among authors: tassone p. Crit Rev Oncol Hematol. 2024 Jan;193:104229. doi: 10.1016/j.critrevonc.2023.104229. Epub 2023 Dec 7. Crit Rev Oncol Hematol. 2024. PMID: 38065404 Free article. Review.
UMG1/CD3ε-bispecific T-cell engager redirects T-cell cytotoxicity against diffuse large B-cell lymphoma.
Caracciolo D, Polerà N, Belmonte B, Conforti F, Signorelli S, Gulino A, Staropoli N, Tuccillo FM, Bonelli P, Juli G, Grillone K, Ascrizzi S, Cirillo M, Migale L, Ballerini A, Pelizon C, Di Martino MT, Tagliaferri P, Riillo C, Tassone P. Caracciolo D, et al. Among authors: tassone p. Br J Haematol. 2024 Feb;204(2):555-560. doi: 10.1111/bjh.19183. Epub 2023 Nov 14. Br J Haematol. 2024. PMID: 37963444
Targeting non-coding RNAs: Perspectives and challenges of in-silico approaches.
Rocca R, Grillone K, Citriniti EL, Gualtieri G, Artese A, Tagliaferri P, Tassone P, Alcaro S. Rocca R, et al. Among authors: tassone p. Eur J Med Chem. 2023 Dec 5;261:115850. doi: 10.1016/j.ejmech.2023.115850. Epub 2023 Oct 9. Eur J Med Chem. 2023. PMID: 37839343 Free article. Review.
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study.
Tassone P, Di Martino MT, Arbitrio M, Fiorillo L, Staropoli N, Ciliberto D, Cordua A, Scionti F, Bertucci B, Salvino A, Lopreiato M, Thunarf F, Cuomo O, Zito MC, De Fina MR, Brescia A, Gualtieri S, Riillo C, Manti F, Caracciolo D, Barbieri V, Di Paola ED, Di Francesco AE, Tagliaferri P. Tassone P, et al. J Hematol Oncol. 2023 Jun 26;16(1):68. doi: 10.1186/s13045-023-01468-8. J Hematol Oncol. 2023. PMID: 37365583 Free PMC article. Clinical Trial.
228 results